Balanced product information
Evidence, limitations and safety — in one consistent format.
This page separates authorised uses from investigational or reported uses. It does not provide personal medical advice or dosing instructions.
Product name
NAD+ with vitamin B12
Catalogue label details describe what is displayed; they do not independently verify composition, quality, batch release or UK marketing authorisation.
What is it?
This catalogue product combines nicotinamide adenine dinucleotide (NAD+), a cellular coenzyme, with vitamin B12. The specific chemical form and quantity of B12 should be confirmed because hydroxocobalamin and cyanocobalamin have different product information.
Authorised vitamin B12 injections are established medicines for particular deficiency states; that does not authorise an NAD+/B12 combination.
Intended / recognised uses
Authorised / recognised uses
- Authorised hydroxocobalamin or cyanocobalamin products are used to treat or prevent diagnosed vitamin B12 deficiency, including deficiency causing anaemia or neurological problems.
- The cause of deficiency determines the formulation, route and duration chosen by a clinician.
Reported / other uses
- The combined product is promoted for energy, mitochondrial or cognitive effects, but those claims are not established for this injection.
- NAD+ wellness or anti-ageing uses remain investigational.
How it works
Vitamin B12 is required for DNA synthesis, red-blood-cell formation and normal neurological function. Replacing a genuine deficiency restores these processes.
NAD+ participates in redox and energy-transfer reactions, but providing it by injection has not been shown to add a clinical benefit to B12 treatment.
Potential benefits / effects
- Appropriate B12 replacement can improve deficiency-related anaemia and prevent or treat some neurological complications, although recovery may be incomplete if treatment is delayed.
- There is no established evidence that adding NAD+ improves outcomes in a person who is not deficient or makes an unverified combination equivalent to a licensed B12 medicine.
Potential benefit is not a guarantee of benefit for any individual.
Risks & warnings
- Risks include injection reactions, hypersensitivity and treatment that masks or delays investigation of the underlying cause of symptoms.
- People with cobalt allergy can react to vitamin B12 products. Rapid correction of severe anaemia can rarely contribute to low potassium.
- The NAD+ component and exact combined formulation add uncertain safety and quality risks.
Possible side effects
Common or recognised with B12 injections
- Injection-site pain, swelling or itching; nausea, diarrhoea, headache, dizziness, flushing or acne-like rash can occur depending on the product.
- Frequency for the exact NAD+/B12 combination is not established.
Serious or urgent concerns
- Anaphylaxis or other serious allergic reaction requires emergency treatment.
- Palpitations, marked weakness or other symptoms during correction of severe anaemia require prompt medical review.
Who should not use it / precautions
- Known cobalt or cobalamin allergy requires specialist advice. The exact B12 form matters for some eye conditions and other contraindications.
- Pregnancy, breastfeeding, childhood, severe anaemia, neurological symptoms, liver or kidney disease and suspected malabsorption require professional assessment.
- Folate status and the cause of deficiency should not be overlooked.
Interactions
- Chloramphenicol can reduce the blood-cell response to B12 treatment.
- Metformin and acid-suppressing medicines can contribute to low B12 over time, while folate treatment can mask some blood signs of B12 deficiency.
- Interactions involving injectable NAD+ are not adequately characterised.
Regulatory / legal status
- Specific vitamin B12 injections are authorised UK medicines, normally prescription-only or supplied within professional care pathways.
- No UK marketing authorisation has been verified for the HELIX 1008mg NAD+/B12 combination; it cannot inherit approval from a B12-only product.
Monitoring / professional supervision
- Assessment should identify the cause of suspected deficiency and may include full blood count, B12, folate and relevant metabolic or antibody tests.
- Clinical response, neurological symptoms and blood-count recovery may need follow-up; potassium may be relevant in severe anaemia.
- A clinician should decide the appropriate formulation and monitoring plan.
Evidence & sources
Sources are selected for regulatory status, recognised uses and material safety information. They do not validate the HELIX-labelled presentation.
- NHS — Hydroxocobalamin overview
- NHS — Side effects of hydroxocobalamin
- BNF — Hydroxocobalamin
- PubMed — Systematic review of NAD+ and precursor supplementation
Sources accessed and content reviewed 12 September 2026. Regulatory status can change; consult the current official record.
Information disclaimer
HELIX — FOR INFORMATION ONLY. NOT FOR SALE.
The products displayed on this website are presented strictly for informational and educational purposes, helping visitors understand their descriptions, features and specifications. No products are offered for sale through this website, and no product orders or payments are accepted through this platform.
The information on this website does not constitute medical advice, a prescription or a recommendation to use any product. Displaying a product does not establish its regulatory approval, safety or suitability for an individual. Please consult an appropriately qualified healthcare professional for personal medical advice.
For a UK-facing website, this disclaimer does not by itself establish legal compliance. Public advertising of prescription-only medicines and advertising of unlicensed medicines are subject to legal restrictions; the catalogue, wording and presentation require appropriate regulatory review.
Licensed-provider information
Where permitted by applicable law, HELIX may display contact details for independent third-party providers whose registration details have been checked against an appropriate official register. Visitors may contact a listed provider directly to enquire about lawful availability and eligibility requirements.
Any supply is subject to the provider’s assessment, applicable regulations, and verification of all required documentation, which may include a valid prescription, professional licence, identification or other authorisation. A referral does not guarantee availability, eligibility or supply.
Registration status can change. Review the provider's regulator, registration number, official-register record and last-checked date, then verify the current status independently before engaging.